Ischemic colitis medical therapy: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 7: Line 7:
==Medical Therapy==
==Medical Therapy==
The medical therapy for ischemic colitis is as follows:<ref>PATH, EJ, McCLURE, JN Jr. Intestinal obstruction; the protective action of sulfasuxidine and sulfathalidine to the ileum following vascular damage. Ann Surg 1950; 131:159.</ref><ref>{{cite journal | author = Plonka A, Schentag J, Messinger S, Adelman M, Francis K, Williams J | title = Effects of enteral and intravenous antimicrobial treatment on survival following intestinal ischemia in rats. | journal = J Surg Res | volume = 46 | issue = 3 | pages = 216-20 | year = 1989 | id = PMID 2921861}}</ref><ref>{{cite journal | author = Bennion R, Wilson S, Williams R | title = Early portal anaerobic bacteremia in mesenteric ischemia. | journal = Arch Surg | volume = 119 | issue = 2 | pages = 151-5 | year = 1984 | id = PMID 6696611}}</ref><ref>{{cite journal | author = Redan J, Rush B, Lysz T, Smith S, Machiedo G | title = Organ distribution of gut-derived bacteria caused by bowel manipulation or ischemia. | journal = Am J Surg | volume = 159 | issue = 1 | pages = 85-9; discussion 89-90 | year = 1990 | id = PMID 2403765}}</ref><ref>Feldman: Sleisenger & Fordtran's Gastrointestinal and Liver Disease, 7th ed., 2002 Saunders, p. 2334.</ref>
The medical therapy for ischemic colitis is as follows:<ref>PATH, EJ, McCLURE, JN Jr. Intestinal obstruction; the protective action of sulfasuxidine and sulfathalidine to the ileum following vascular damage. Ann Surg 1950; 131:159.</ref><ref>{{cite journal | author = Plonka A, Schentag J, Messinger S, Adelman M, Francis K, Williams J | title = Effects of enteral and intravenous antimicrobial treatment on survival following intestinal ischemia in rats. | journal = J Surg Res | volume = 46 | issue = 3 | pages = 216-20 | year = 1989 | id = PMID 2921861}}</ref><ref>{{cite journal | author = Bennion R, Wilson S, Williams R | title = Early portal anaerobic bacteremia in mesenteric ischemia. | journal = Arch Surg | volume = 119 | issue = 2 | pages = 151-5 | year = 1984 | id = PMID 6696611}}</ref><ref>{{cite journal | author = Redan J, Rush B, Lysz T, Smith S, Machiedo G | title = Organ distribution of gut-derived bacteria caused by bowel manipulation or ischemia. | journal = Am J Surg | volume = 159 | issue = 1 | pages = 85-9; discussion 89-90 | year = 1990 | id = PMID 2403765}}</ref><ref>Feldman: Sleisenger & Fordtran's Gastrointestinal and Liver Disease, 7th ed., 2002 Saunders, p. 2334.</ref>
* Treatment is determined by its severity
** Precipitating factors such as sepsis, hypotension, poor cardiac function, hypovolaemia and hypoxia should be addressed, and precipitating drugs withdrawn.
* Fluid resuscitation
** intravenous fluids
** bowel rest
** nasogastric tube
** total parenteral nutrition if prolonged bowel rest
* Patients with colonic dilatation are managed with insertion of a rectal tube or endoscopic decompression.
* Antibiotic use in animal studies has demonstrated reduced duration and severity of IC, and prevention of bacterial translocation through damaged mucosa.
** A study involving dogs demonstrated reduction in vessel thrombosis and increased survival.
* The role of antibiotic therapy in limiting the duration and severity of IC in humans requires further research.
* There is no evidence available about the role of anticoagulation or antiplatelet therapy in acute presentations of IC, prevention of recurrence or in mitigating death from vascular causes.
** Antiplatelets have an established role in limiting tissue injury in ischemia and ischemia-reperfusion events, such as stroke and acute myocardial infarction.
** Further research into potential benefits of antiplatelets may be warranted.
* Steroids have not been shown to improve outcomes.


===Intravenous Fluids===
===Intravenous Fluids===

Revision as of 16:33, 5 January 2018

Colitis Main Page

Ischemic colitis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Ischemic colitis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Abdominal X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Ischemic colitis medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Ischemic colitis medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA onIschemic colitis medical therapy

CDC on Ischemic colitis medical therapy

Ischemic colitis medical therapy in the news

Blogs on Ischemic colitis medical therapy

Directions to Hospitals Treating Ischemic colitis

Risk calculators and risk factors for Ischemic colitis medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Hamid Qazi, MD, BSc [2]

Overview

Except in the most severe cases, ischemic colitis is treated with supportive care.

Medical Therapy

The medical therapy for ischemic colitis is as follows:[1][2][3][4][5]

  • Treatment is determined by its severity
    • Precipitating factors such as sepsis, hypotension, poor cardiac function, hypovolaemia and hypoxia should be addressed, and precipitating drugs withdrawn.
  • Fluid resuscitation
    • intravenous fluids
    • bowel rest
    • nasogastric tube
    • total parenteral nutrition if prolonged bowel rest
  • Patients with colonic dilatation are managed with insertion of a rectal tube or endoscopic decompression.
  • Antibiotic use in animal studies has demonstrated reduced duration and severity of IC, and prevention of bacterial translocation through damaged mucosa.
    • A study involving dogs demonstrated reduction in vessel thrombosis and increased survival.
  • The role of antibiotic therapy in limiting the duration and severity of IC in humans requires further research.
  • There is no evidence available about the role of anticoagulation or antiplatelet therapy in acute presentations of IC, prevention of recurrence or in mitigating death from vascular causes.
    • Antiplatelets have an established role in limiting tissue injury in ischemia and ischemia-reperfusion events, such as stroke and acute myocardial infarction.
    • Further research into potential benefits of antiplatelets may be warranted.
  • Steroids have not been shown to improve outcomes.

Intravenous Fluids

  • IV fluids are given to treat dehydration, and the patient is placed on bowel rest (meaning nothing to eat or drink) until the symptoms resolve.

Optimize Cardiac Output

  • If possible, cardiac function and oxygenation should be optimized to improve oxygen delivery to the ischemic bowel.

Nasogastric Tube

Antibiotics

  • Antibiotics are sometimes given in moderate to severe cases. The data supporting this practice dates to the 1950s. More recent animal data suggests that antibiotics may increase survival and prevent bacteria from crossing the damaged lining of the colon into the bloodstream.
  • The use of prophylactic antibiotics in ischemic colitis has not been prospectively evaluated in humans, but many authorities recommend their use based on the animal data.

Contraindicated medications

Ischemic colitis is considered an absolute contraindication to the use of the following medications:

References

  1. PATH, EJ, McCLURE, JN Jr. Intestinal obstruction; the protective action of sulfasuxidine and sulfathalidine to the ileum following vascular damage. Ann Surg 1950; 131:159.
  2. Plonka A, Schentag J, Messinger S, Adelman M, Francis K, Williams J (1989). "Effects of enteral and intravenous antimicrobial treatment on survival following intestinal ischemia in rats". J Surg Res. 46 (3): 216–20. PMID 2921861.
  3. Bennion R, Wilson S, Williams R (1984). "Early portal anaerobic bacteremia in mesenteric ischemia". Arch Surg. 119 (2): 151–5. PMID 6696611.
  4. Redan J, Rush B, Lysz T, Smith S, Machiedo G (1990). "Organ distribution of gut-derived bacteria caused by bowel manipulation or ischemia". Am J Surg. 159 (1): 85–9, discussion 89-90. PMID 2403765.
  5. Feldman: Sleisenger & Fordtran's Gastrointestinal and Liver Disease, 7th ed., 2002 Saunders, p. 2334.


Template:WikiDoc Sources